Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED

NCT05520723 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer
Breast Cancer
Advanced HR+/HER2- Breast Cancer

Interventions

DRUG: Sacituzumab govitecan
DRUG: Loperamide
DRUG: Granulocyte Colony-Stimulating Factor

Sponsor

MedSIR

Collaborators

[object Object]